Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Dazukibart by Pfizer for Systemic Lupus Erythematosus: Likelihood of Approval
Dazukibart is under clinical development by Pfizer and currently in Phase II for Systemic Lupus Erythematosus. According to GlobalData, Phase...
Risk adjusted net present value: What is the current valuation of Pfizer's Dazukibart?
Dazukibart is a monoclonal antibody commercialized by Pfizer, with a leading Phase III program in Dermatomyositis. According to Globaldata, it...
Risk adjusted net present value: What is the current valuation of Pfizer's Dazukibart?
Dazukibart is a monoclonal antibody commercialized by Pfizer, with a leading Phase III program in Polymyositis. According to Globaldata, it...